Influence of CYP2C19*17 Genetic Polymorphism on the Steady-State Concentration of Escitalopram in Patients with Recurrent Depressive Disorder
The CYP2C19*17 genetic variant significantly affected the efficacy and safety profiles of escitalopram in a group of 267 patients with recurrent depressive disorder but did not greatly affect its equilibrium plasma concentration.
Authors
- Freeborn Rwere (ORCID: https://orcid.org/0000-0002-7037-6850)
- I A Zaytsev
- А. Е. Петухов (ORCID: https://orcid.org/0000-0002-4855-4235)
- E. P. Pankratenko (ORCID: https://orcid.org/0000-0002-2612-439X)
- Evgeny Bryun (ORCID: https://orcid.org/0000-0002-9329-1155)
- Roman Vlasovskih
- V A Ivanchenko
- Denis Horyaev
- S A Pozdniakov
- V V Noskov
- N V Vinokurova
- Valentin Yurievich Skryabin (ORCID: https://orcid.org/0000-0002-4942-8556)
- Dmitry Alekseevich Sychev (ORCID: https://orcid.org/0000-0002-4496-3680)
- Михаил Сергеевич Застрожин (ORCID: https://orcid.org/0000-0002-3964-9726)
Institutions
- Russian Medical Academy of Continuous Professional Education (RU)
Publication Details
- Journal
- Psychopharmacology Bulletin
- Published
- 2025-08-12
- DOI
- https://doi.org/10.64719/pb.4440
- Citations
- 5
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 4.18